中国临床研究2024,Vol.37Issue(1) :136-140,146.DOI:10.13429/j.cnki.cjcr.2024.01.028

Janus激酶抑制剂在皮肤病中的应用研究进展

Research progress in the application of Janus kinase inhibitors in dermatosis

王思宇 牛旭平
中国临床研究2024,Vol.37Issue(1) :136-140,146.DOI:10.13429/j.cnki.cjcr.2024.01.028

Janus激酶抑制剂在皮肤病中的应用研究进展

Research progress in the application of Janus kinase inhibitors in dermatosis

王思宇 1牛旭平2
扫码查看

作者信息

  • 1. 山西医科大学第九临床医学院,山西太原 030000
  • 2. 太原中心医院皮肤科,山西太原 030009
  • 折叠

摘要

Janus激酶(JAK)抑制剂是多种抑制酪氨酸激酶的分子的总称,主要针对JAK-信号转导子和转录激活子(JAK-STAT)信号通路所涉及的多种酶及转录因子的抑制,对多种涉及这一通路的炎症免疫相关性及其他皮肤病都有显著疗效,成为目前皮肤病研究的热点.本文主要针对JAK抑制剂在相关皮肤病中的作用机制、研究进展及应用注意事项进行综述,以期为相关皮肤病的临床研究及治疗提供思路.

Abstract

The Janus kinase(JAK)inhibitors are a collective term for various molecules that inhibit tyrosine kinase,mainly targeting the inhibition of various enzymes and transcription factors involved in the Janus kinase and signal transducer and activator of transcription(JAK-STAT)signaling pathway.It has significant therapeutic effects on a variety of inflammatory immune-related and other dermatosis involved in this pathway,which has become a hot spot in dermatological research.This article mainly reviews the mechanism of action,research progress and precautions of JAK inhibitors in related dermatosises,in order to provide ideas for clinical research and treatment of related dermatosises.

关键词

皮肤病/Janus激酶信号转导和转录激活因子信号通路/Janus激酶抑制剂/免疫调节

Key words

Dermatosis/Janus kinase and signal transducer and activator of transcription signaling pathway/Janus kinase inhibitor/Immunoregulation

引用本文复制引用

基金项目

山西省医学重点科研项目(2022143)

出版年

2024
中国临床研究
中华预防医学会

中国临床研究

CSTPCD
影响因子:0.943
ISSN:1674-8182
参考文献量2
段落导航相关论文